Publication

Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation

Patel, M.
; 
Lee, J. S.
; 
De Miguel, M. J.
; 
Burns, T.
; 
Gonzalez, A. F.
; 
Kim, T. W.
; 
Krebs, Matthew G
; 
Prenen, H.
; 
Shmueli, E. S.
; 
Desai, J.
... show 9 more
Citations
Altmetric:
Abstract
Authors
Patel, M.
Lee, J. S.
De Miguel, M. J.
Burns, T.
Gonzalez, A. F.
Kim, T. W.
Krebs, Matthew G
Prenen, H.
Shmueli, E. S.
Desai, J.
Lorusso, P.
Sacher, A.
Choi, Y.
Dharia, N.
Lin, M. T.
Mandlekar, S.
Royer-Joo, S.
Schutzman, J. L.
Garralda, E.
Affiliation
Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute,Sarasota, FL
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Patel M, Lee JS, De Miguel MJ, Burns T, Gonzalez AF, Kim TW, et al. Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation. Annals of Oncology. 2022 Sep;33(7):S749-S. PubMed PMID: WOS:000866211600453.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625956
Embedded videos